leadf
logo-loader
viewIXICO PLC

Phytopharm plummets on phase II trial disappointment

drug_research_v2_350_51223d91ced18.jpg

 

Phytopharm (LON:PYM) shares fell out of bed with a bang this morning after a setback on its Parkinson’s disease treatment, Cogane.

Analysis of the headline results from a Phase II trial in unmedicated patients with early-stage Parkinson’s disease indicated that Cogane had no beneficial effects on patients' symptoms measured by the primary or secondary endpoints in the study.

Review of the safety data confirmed that Cogane administered orally once daily for up to 28 weeks was well tolerated.

The full results of the study will be published in an appropriate scientific forum in due course.

Professor Warren Olanow, professor of Neurology and Neuroscience at Mount Sinai Medical School and co-chief investigator for the study expressed disappointment at the result.

"Trophic factors that enhance and restore function to remaining nerve cells is an extremely promising approach for the treatment of neurodegenerative disorders such as Parkinson's disease. Cogane offered the potential of providing trophic effects throughout the brain with an oral medication that was relatively safe and well tolerated. The company is to be congratulated for carrying out this important study in such a high quality manner. Sadly, the results are negative,” Professor Olanow said.

“We are naturally disappointed with the outcome of this study of Cogane in patients with Parkinson's disease. Cogane had demonstrated encouraging efficacy in a wide range of industry standard pre-clinical models but this promise has not translated into clinically meaningful efficacy in this study,” said Tim Sharpington, chief executive officer of Phytopharm.

"Cogane’s future now looks bleak – we do not view potential development for amyotrophic lateral sclerosis (ALS) as viable – and we are not surprised the stock is trading close to Phytopharm’s £5.5m cash balance," said Edison Research.

"The company is conducting a strategic review and we believe the best outcome may be a reverse merger by a private company seeking to utilise Phytopharm’s cash, LSE listing and £55m in accumulated tax losses," the research house added.

Shares in Phytopharm were down by 81% to 1,92p in afternoon trading.

 

Quick facts: IXICO PLC

Price: 118.5 GBX

AIM:IXI
Market: AIM
Market Cap: £55.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

IXICO plays 'pivotal role' after announcing £2m extension to Huntington's...

IXICO PLC's (LON:IXI) Lammert Albers talks to Proactive London about the £2m extension to a contract to provide additional imaging services for a pivotal Huntington's disease (HD) study. Albers describes this as a 'strong suit' having started very early and now carrying out a Phase III...

on 09/29/2020

2 min read